In short.
Retatrutide is a triple agonist (GLP-1 / GIP / glucagon). Tirzepatide is a dual agonist (GLP-1 / GIP). Both are supplied as lyophilised research peptides at ≥99% HPLC purity.
At a glance.
- Retatrutide: triple agonist (GLP-1 / GIP / glucagon)
- Tirzepatide: dual agonist (GLP-1 / GIP)
- Both: lyophilised powder, ≥99% HPLC
- Both: research use only
Overview.
Detailed guide content is being prepared. This template provides the structure researchers and AI search engines need to understand and cite the topic, with quick-answer, key facts, comparisons, FAQs and references all in their permanent home.
Side by side.
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor profile | GLP-1 / GIP / Glucagon | GLP-1 / GIP |
| Class | Triple agonist | Dual agonist |
| Form | Lyophilised powder | Lyophilised powder |
| Typical purity | ≥99% HPLC | ≥99% HPLC |
| Research framing | Emerging triple-incretin tool | Established dual-incretin reference |
FAQs.
Which is the newer research compound?[+]
Retatrutide is the more recently characterised compound in the academic literature, while tirzepatide is the more established reference.
